Cardan Capital Partners’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Cardan Capital Partners’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$4.09M	Buy	89,900 +21,230	+31%	+$974K	0.46%	70
2021 Q2	$3.36M	Sell	68,670 -322	-0.5%	-$15.4K	0.37%	83
2021 Q1	$3.47M	Buy	68,992 +16,272	+31%	+$901K	0.42%	75
2020 Q4	$2.7M	Buy	52,720 +2,555	+5%	+$122K	0.33%	84
2020 Q3	$2.06M	Sell	50,165 -7,419	-13%	-$306K	0.27%	104
2020 Q2	$2.41M	Buy	57,584 +11,668	+25%	+$460K	0.34%	94
2020 Q1	$1.46M	Sell	45,916 -26,338	-36%	-$1.01M	0.24%	90
2019 Q4	$3.06M	Buy	72,254 +4,887	+7%	+$181K	0.41%	67
2019 Q3	$2.13M	Buy	67,367 +11,840	+21%	+$416K	0.3%	82
2019 Q2	$2.01M	Buy	55,527 +6,403	+13%	+$221K	0.3%	77
2019 Q1	$1.78M	Buy	+49,124	New	+$1.64M	0.29%	76

Other funds holding SBIO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Cardan Capital Partners's SBIO Position: Q3 2021 in Review

Cardan Capital Partners increased its ALPS Medical Breakthroughs ETF (SBIO) stake by 31% in Q3 2021, buying an estimated $974K and bringing the position to 89,900 shares worth $4.09M. The position accounts for 0.46% of the portfolio, ranked #70.

Cardan Capital Partners first reported a position in SBIO in Q1 2019 and has held it in 11 quarters since. 60 funds tracked by Wall St. Rank hold SBIO as of Q3 2021.

Cardan Capital Partners held 89,900 shares of ALPS Medical Breakthroughs ETF worth $4.09M as of Q3 2021.
Cardan Capital Partners bought 21,230 ALPS Medical Breakthroughs ETF shares in Q3 2021, an estimated $974K.
ALPS Medical Breakthroughs ETF made up 0.46% of Cardan Capital Partners's portfolio in Q3 2021, its #70 holding.
Cardan Capital Partners first reported a position in ALPS Medical Breakthroughs ETF in Q1 2019 and has held it in 11 quarters since.
60 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2021.

Based on Cardan Capital Partners's 13F filing for Q3 2021, filed 25 Oct 2021.